Please wait a minute...
浙江大学学报(医学版)  2021, Vol. 50 Issue (6): 707-715    DOI: 10.3724/zdxbyxb-2021-0222
专题报道     
持续/复发性分化型甲状腺癌综合治疗相关预后因素分析
王健行,姚瑶,钱亦淳,姚卫萍,程帅,袁欣越,张园()
南京医科大学附属肿瘤医院 江苏省肿瘤医院 江苏省肿瘤防治研究所头颈外科,江苏 南京 210009
Prognostic factors in patients with persistent/recurrent differentiated thyroid carcinoma after comprehensive treatment
WANG Jianxing,YAO Yao,QIAN Yichun,YAO Weiping,CHENG Shuai,YUAN Xinyue,ZHANG Yuan()
Department of Head and Neck Surgery, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
 全文: PDF(3034 KB)   HTML( 2 )
摘要:

目的:分析持续/复发性分化型甲状腺癌(DTC)尤其是外侵型持续/复发性DTC患者综合治疗后的相关预后因素。方法:回顾性分析2011年8月至2021年6月于江苏省肿瘤医院头颈外科进行再次手术的525例DTC患者的临床资料,分析影响持续/复发性DTC尤其是外侵型持续/复发性DTC综合治疗后总生存时间和无复发生存时间的相关预后因素。结果: 525例患者中,行甲状腺区手术318例,行颈部中央淋巴结清扫359例,行颈外侧淋巴结清扫409例。493例随访患者的5年总存活率和无复发存活率分别为95.10%和89.60%,8年总存活率和无复发存活率分别为91.80%和81.30%。回归分析结果显示,复发后再次手术时55岁及以上、男性和远处转移是影响持续/复发性DTC患者综合治疗后总生存时间的独立危险因素(均P<0.05),甲状腺和淋巴结同时外侵、多器官外侵和既往手术次数2次及以上是影响持续/复发性DTC患者综合治疗后无复发生存时间的独立危险因素(均P<0.05);复发后再次手术时55岁及以上和男性是影响外侵型持续/复发性DTC患者总生存时间的独立危险因素(均P<0.05),多器官外侵和既往手术次数2次及以上是影响外侵型持续/复发性DTC患者无复发生存时间的独立危险因素(均P<0.05)。结论:复发后再次手术时55岁及以上、男性和远处转移的持续/复发性DTC患者死亡风险较高,甲状腺和淋巴结同时外侵、多器官外侵以及既往手术次数2次及以上的患者更易复发。复发后再次手术时55岁及以上和男性外侵型持续/复发性DTC患者死亡风险较高,多器官外侵和既往手术次数2次及以上的外侵型持续/复发性DTC患者更易复发。

关键词: 分化型甲状腺癌持续/复发局部晚期多学科综合治疗预后回顾性研究    
Abstract:

Objective: To investigate the prognostic factors of patients with persistent/recurrent differentiated thyroid carcinoma (DTC) especially with external invasive persistent recurrent DTC after comprehensive treatment. Methods: The clinical data of 525 patients with persistent/recurrent DTC who underwent surgical treatment from August 2011 to June 2021 in the Department of Head and Neck Surgery of Jiangsu Cancer Hospital were retrospectively analyzed. The prognostic factors affecting overall survival (OS) and relapse-free survival (RFS) of persistent/recurrent DTC, especially external invasive persistent/recurrent DTC were analyzed. Results: Among 525 patients, 318 patients underwent thyroidectomy, 359 patients underwent central lymph node dissection, and 409 patients underwent lateral cervical lymph node dissection. Among 493 followed-up patients, 5-year OS and RFS were 95.10% and 89.60%, 8-year OS and RFS were 91.80% and 81.30%. Cox regression analysis showed that in patients with persistent/recurrent DTC after comprehensive treatment, age ≥55?years at reoperation after recurrence, male gender and distant metastasis were independent risk factors of OS (all P<0.05); while the simultaneous invasion of thyroid and lymph nodes, multiple organ invasion and the number of previous operations ≥2 were independent risk factors of RFS (allP<0.05). In patients with external invasive persistent/recurrent DTC after comprehensive treatment, age ≥55?years at reoperation after recurrence and male gender were independent risk factors of OS (bothP<0.05); while multiple organ invasion and the number of previous operations ≥2 were independent risk factors of RFS (bothP<0.05).Conclusions: Male patients aged 55?years old and above, with distant metastasis have a higher risk of poorer prognosis in persistent/recurrent DTC; while patients with simultaneous external invasion of thyroid and lymph nodes, multiple organ invasion and the number of previous operations ≥2 are more likely to relapse. For external invasive persistent/recurrent DTC, male patients aged 55?years old and above have a higher risk of poorer prognosis; while patients with multiple organ invasion and the number of previous operations ≥2 are more likely to have recurrence.

Key words: Differentiated thyroid carcinoma    Persistent/recurrent    Locally advanced    Multidisciplinary comprehensive treatment    Prognosis    Retrospective studies
收稿日期: 2021-08-06 出版日期: 2022-03-22
CLC:  R736.1  
基金资助: 江苏省社会发展重点研发计划(BE2016796)
通讯作者: 张园     E-mail: yzhang1963@163.com
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  
王健行
姚瑶
钱亦淳
姚卫萍
程帅
袁欣越
张园

引用本文:

王健行,姚瑶,钱亦淳,姚卫萍,程帅,袁欣越,张园. 持续/复发性分化型甲状腺癌综合治疗相关预后因素分析[J]. 浙江大学学报(医学版), 2021, 50(6): 707-715.

WANG Jianxing,YAO Yao,QIAN Yichun,YAO Weiping,CHENG Shuai,YUAN Xinyue,ZHANG Yuan. Prognostic factors in patients with persistent/recurrent differentiated thyroid carcinoma after comprehensive treatment. J Zhejiang Univ (Med Sci), 2021, 50(6): 707-715.

链接本文:

https://www.zjujournals.com/med/CN/10.3724/zdxbyxb-2021-0222        https://www.zjujournals.com/med/CN/Y2021/V50/I6/707

图 1  持续/复发性分化型甲状腺癌(DTC)患者的治疗流程
图 2  持续/复发性分化型甲状腺癌患者综合治疗后的生存曲线

临床特征

单因素分析

多因素分析

HR

95%CI

P

HR

95%CI

P

复发后再次手术时55岁及以上

14.152

4.120~48.612

<0.01

13.595

3.816~48.432

<0.01

男性

5.687

2.047~15.798

<0.01

4.187

1.423~12.322

<0.01

不同组织外侵无

1.000

甲状腺外侵

1.931

0.581 ~ 6.419

>0.05

淋巴结外侵

1.417

0.414 ~ 4.848

>0.05

同时外侵

>0.05

器官外侵程度无

1.000

单器官外侵

2.024

0.643 ~ 6.368

>0.05

多器官外侵

1.007

0.252 ~ 4.032

>0.05

远处转移

6.154

2.500~15.151

<0.01

3.526

1.265~9.833

<0.05

再次术后碘治疗

2.765

1.123~6.810

<0.05

既往手术次数2次及以上

0.330

0.044~2.473

>0.05

表 1  持续/复发性分化型甲状腺癌患者综合治疗后总生存时间影响因素的回归分析结果

临床特征

单因素分析

多因素分析

HR

95%CI

P

HR

95%CI

P

复发后再次手术时55岁及以上

1.004

0.516~1.951

>0.05

男性

1.431

0.784~2.610

>0.05

不同组织外侵无

1.000

1.000

甲状腺外侵

1.755

0.767~4.012

>0.05

3.288

1.424~7.588

>0.05

淋巴结外侵

1.459

0.638~3.336

>0.05

3.350

1.397~8.037

>0.05

同时外侵

13.638

5.056~36.784

<0.01

12.270

4.406~34.174

<0.01

器官外侵程度无

1.000

1.000

单器官外侵

0.340

0.105~1.103

>0.05

1.304

0.301~5.646

>0.05

多器官外侵

4.346

2.079~9.089

<0.01

11.924

4.285~33.185

<0.01

远处转移

2.783

1.432~5.411

<0.01

1.039

0.431~2.504

>0.05

再次术后碘治疗

1.661

0.890~3.101

>0.05

既往手术次数2次及以上

13.853

7.401~25.927

<0.01

11.716

6.012~22.830

<0.01

表 2  持续/复发性分化型甲状腺癌患者综合治疗后无复发生存时间影响因素的回归分析结果
图 3  外侵型持续/复发性分化型甲状腺癌患者综合治疗后的生存曲线

临床特征

单因素分析

多因素分析

HR

95%CI

P

HR

95%CI

P

复发后再次手术时55岁及以上

36.209

4.761~275.402

<0.01

31.288

4.029~242.990

<0.01

男性

6.754

1.906~23.935

<0.01

4.592

1.239~17.021

<0.05

不同组织外侵 甲状腺外侵

1.000

淋巴结外侵

0.733

0.266~2.023

>0.05

同时外侵

>0.05

器官外侵程度单器官外侵

1.000

多器官外侵

0.571

0.165~1.624

>0.05

远处转移

6.377

2.312~17.587

<0.01

2.946

0.934~9.287

>0.05

再次术后碘治疗

3.045

1.104~8.397

<0.05

1.655

0.549~4.988

>0.05

既往手术次数2次及以上

0.387

0.051~2.946

>0.05

表 3  外侵型持续/复发性分化型甲状腺癌患者综合治疗后总生存时间影响因素的回归分析结果

临床特征

单因素分析

多因素分析

HR

95%CI

P

HR

95%CI

P

复发后再次手术时55岁及以上

1.076

0.515~2.244

>0.05

男性

1.290

0.660~2.519

>0.05

不同组织外侵甲状腺外侵

1.000

1.000

淋巴结外侵

0.822

0.402~1.682

>0.05

0.966

0.456~2.047

>0.05

同时外侵

7.844

3.186~19.315

<0.01

2.458

0.830~7.277

>0.05

器官外侵程度单器官外侵

1.000

1.000

多器官外侵

12.031

4.246~34.088

<0.01

8.934

3.072~26.865

<0.01

远处转移

2.981

1.456~6.103

<0.01

1.161

0.435~3.096

>0.05

再次术后碘治疗

1.737

0.874~3.454

>0.05

既往手术次数2次及以上

17.982

8.588~37.652

<0.01

16.156

7.035~37.107

<0.01

表 4  外侵型持续/复发性分化型甲状腺癌患者综合治疗后无复发生存时间的回归分析结果
1 SUNGH, FERLAYJ, SIEGELR L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]CA Cancer J Clin, 2021, 71( 3): 209-249.
doi: 10.3322/caac.21660
2 TRIMBOLIP, CASTELLANAM, PICCARDOA, et al.The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma. A meta-analysis[J]Rev Endocr Metab Disord, 2021, 22( 2): 453-460.
doi: 10.1007/s11154-020-09592-3
3 RUIZE M L, NIUT, ZERFAOUIM, et al.A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer[J]Surgery, 2020, 167( 1): 73-79.
doi: 10.1016/j.surg.2019.06.058
4 张丽林, 赵留芳, 李晓江. 复发转移性分化型甲状腺癌诊疗进展[J]. 国际耳鼻咽喉头颈外科杂志, 2018, 42(3): 149-153
ZHANG Lilin, ZHAO Liufang, LI Xiaojiang. Progress in diagnosis and treatment of recurrent or metastatic differentiated thyriod cancer[J]. International Journal of Otolaryngology-Head and Neck Surgery, 2018, 42(3): 149-153. (in Chinese)
5 林岩松, 张彬, 梁智勇, 等. 复发转移性分化型甲状腺癌诊治共识[J]. 中国癌症杂志, 2015, 25(7): 481-496
LIN Yansong, ZHANG Bin, LIANG Zhiyong, et al. Consensus on diagnosis and treatment of recurrent metastatic differentiated thyroid carcinoma[J]. China Oncology, 2015, 25(7): 481-496. (in Chinese)
6 中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组,?中国抗癌协会头颈肿瘤专业委员会,?等.甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华核医学与分子影像杂志, 2013, 33(2): 96-115
Chinese Society of Endocrinology, Chinese Society of Surgery of Chinese Medical Association Endocrinology Group, Chinese Association of Head and Neck Oncology, et al. Guidelines for the diagnosis and treatment of thyroid nodules and differentiated thyroid carcinoma[J]. Chinese Journal of Nuclear Medicine and Molecular Imaging, 2013, 33(2): 96-115. (in Chinese)
7 AMINM B, GREENEF L, EDGES B, et al.The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging[J]CA-Cancer J Clin, 2017, 67( 2): 93-99.
doi: 10.3322/caac.21388
8 CARLINGT, UDELSMANR. Thyroid cancer[J]Annu Rev Med, 2014, 65( 1): 125-137.
doi: 10.1146/annurev-med-061512-105739
9 邹华伟, 项承. 异嗜性和多变性逆转录病毒受体1在乳头状甲状腺癌患者中表达的意义[J]. 浙江大学学报(医学版), 2021, 50(1): 90-96
ZOU Huawei, XIANG Cheng. Clinical implication of xenotropic and polytropic retrovirus receptor 1 in papillary thyroid carcinoma[J]. 2021, 50(1): 90-96. (in Chinese)
10 LANGB H H, LOC Y, CHANW F, et al.Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging[J]Ann Surg Oncol, 2007, 14( 2): 730-738.
doi: 10.1245/s10434-006-9207-5
11 SHOKOOHIA, BERTHELETE, GILLS, et al.Treatment for recurrent differentiated thyroid cancer: a canadian population based experience[J/OL]Cureus, 2020, 12( 2): e7122.
doi: 10.7759/cureus.7122
12 TAMS, BOONSRIPITAYANONM, AMITM, et al.Survival in differentiated thyroid cancer: comparing the AJCC cancer staging seventh and eighth editions[J]Thyroid, 2018, 28( 10): 1301-1310.
doi: 10.1089/thy.2017.0572
13 NIXONI J, SIMOR, NEWBOLDK, et al.Management of invasive differentiated thyroid cancer[J]Thyroid, 2016, 26( 9): 1156-1166.
doi: 10.1089/thy.2016.0064
14 DINGJ, WUW, FANGJ, et al.Male sex is associated with aggressive behaviour and poor prognosis in Chinese papillary thyroid carcinoma[J]Sci Rep, 2020, 10( 1): 4141.
doi: 10.1038/s41598-020-60199-9
15 ZAHEDIA, BONDAZL, RAJARAMANM, et al.Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation[J]Thyroid, 2020, 30( 6): 871-877.
doi: 10.1089/thy.2018.0775
16 WANGX, WANGX L. Prognostic analysis of recurrence in children and adolescents with differentiated thyroid cancer[J]Chin Med J, 2020, 133( 19): 2281-2286.
doi: 10.1097/CM9.0000000000000910
17 黄璐, 李超, 王薇, 等.甲状腺癌腺外侵犯的意义及最新研究进展[J]. 中华耳鼻咽喉头颈外科杂志, 2019, 54(9): 717-720
HUANG Lu, LI Chao, WANG Wei, et al. The significance and latest progress of extrathyroidal extension of thyroid cancer[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2019, 54(9): 717-720. (in Chinese)
18 PARKJ, KIMK, LIMD J, et al.Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study[J]Sci Rep, 2021, 11( 1): 14908.
doi: 10.1038/s41598-021-94461-5
19 HAUGENB R, ALEXANDERE K, BIBLEK C, et al.2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]Thyroid, 2016, 26( 1): 1-133.
doi: 10.1089/thy.2015.0020
20 TIWARIY, KRISHNAMURTHYA. Long-term outcomes of differentiated thyroid cancers with tracheal invasion: a 15-year experience[J]Indian J Cancer, 2020, 57( 4): 398-404.
doi: 10.4103/ijc.IJC_456_19
21 GRANIG, RAMUNDOV, VERRIENTIA, et al.Thyroid hormone therapy in differentiated thyroid cancer[J]Endocrine, 2019, 66( 1): 43-50.
doi: 10.1007/s12020-019-02051-3
22 TUTTLER M, AHUJAS, AVRAMA M, et al.Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association[J]Thyroid, 2019, 29( 4): 461-470.
doi: 10.1089/thy.2018.0597
23 YAOY, CHENGS, XUX, et al.Prognostic factors and the effect of radioiodine on patients with locally advanced differentiated thyroid cancer[J]Ann Transl Med, 2020, 8( 15): 928.
doi: 10.21037/atm-18-1301
24 SAMHOURIL, KRIZJ, ELSAYADK, et al.The role of radiotherapy for patients with thyroid cancer in the modern era[J]Anticancer Res, 2020, 40( 6): 3379-3386.
doi: 10.21873/anticanres.14321
[1] 于玥,凌诗颖,帅瑞雪,邱文娟,张惠文,梁黎黎,季文君,刘宇超,顾学范,韩连书. 720例甲基丙二酸血症MMACHC基因c.609G>A突变患者临床特征及随访分析[J]. 浙江大学学报(医学版), 2021, 50(4): 436-443.
[2] 施锦波,励夏炜,吴育连. 基于SEER数据库分析早期胰腺导管腺癌患者能否从常用术后化疗方案中获益[J]. 浙江大学学报(医学版), 2021, 50(3): 375-382.
[3] 邹华伟,项承. 异嗜性和多变性逆转录病毒受体 1在乳头状甲状腺癌患者中表达的意义[J]. 浙江大学学报(医学版), 2021, 50(1): 90-96.
[4] 李占鲁,黄翯,张文斌,王敏,傅国胜. 冠状动脉CT血管造影提示临界病变有易损斑块患者预后分析[J]. 浙江大学学报(医学版), 2020, 49(1): 76-81.
[5] 米爽,吴燕君,洪正华,王章富,冯兴兵,郑光彬. TLR4/MyD88/NF-κB通路基因及相关炎症因子在继发性脊髓损伤患者中的表达[J]. 浙江大学学报(医学版), 2019, 48(6): 609-616.
[6] 王林燕,薛佳金,陈益,吕成杰,黄寿奖,钭金法,高志刚,陈青江. 新生儿环状胰腺的临床诊治分析[J]. 浙江大学学报(医学版), 2019, 48(5): 481-486.
[7] 马东,赖登明,赵晓霞,胡书奇,吕成杰,黄寿奖,秦琪,钭金法. Ⅲ-b型先天性肠闭锁患儿的治疗[J]. 浙江大学学报(医学版), 2019, 48(5): 487-492.
[8] 王展,唐达星,田红娟,杨帆,温弘,王军梅,陶畅. 肾盂前后径对肾积水胎儿出生后是否手术的预测价值[J]. 浙江大学学报(医学版), 2019, 48(5): 493-498.
[9] 王雅芸,陈原,杨蒙蒙,习芳芳,占琪涛,蒋颖,赵柏惠,罗琼. 淋巴水囊瘤或颈部组织增厚胎儿预后分析[J]. 浙江大学学报(医学版), 2019, 48(4): 434-438.
[10] 张丹丹,王军梅. 胎儿肝血管瘤的产前影像学诊断和管理[J]. 浙江大学学报(医学版), 2019, 48(4): 439-445.
[11] 童凡,杨茹莱,刘畅,吴鼎文,张婷,黄新文,洪芳,钱古柃,黄晓磊,周雪莲,舒强,赵正言. 新生儿酪氨酸血症筛查及基因谱分析[J]. 浙江大学学报(医学版), 2019, 48(4): 459-464.
[12] 钟晚思, 陈智才, 陈红芳, 徐冬娟, 王志敏, 胡海芳, 吴承龙, 张晓玲, 马小董, 王亚仙, 胡海涛, 楼敏, 浙江省缺血性脑卒中静脉溶栓的临床行为干预研究协作组 . 院前急救医疗服务对缺血性脑卒中患者静脉溶栓预后的影响[J]. 浙江大学学报(医学版), 2019, 48(3): 241-246.
[13] 陈红芳, 龚筱弦, 徐冬娟, 王志敏, 胡海芳, 吴承龙, 张晓玲, 马小董, 王亚仙, 胡海涛, 楼敏, 陈智才, 浙江省缺血性脑卒中静脉溶栓的临床行为干预研究协作组 . 治疗时间提前可改善缺血性脑卒中患者再灌注治疗的预后[J]. 浙江大学学报(医学版), 2019, 48(3): 247-253.
[14] 陶安阳, 王志敏, 陈红芳, 徐冬娟, 胡海芳, 吴承龙, 张晓玲, 马小董, 王亚仙, 胡海涛, 楼敏, 浙江省缺血性脑卒中静脉溶栓的临床行为干预研究协作组 . 合并心房颤动对缺血性脑卒中患者静脉溶栓后颅内出血转化的影响[J]. 浙江大学学报(医学版), 2019, 48(3): 254-259.
[15] 张聪聪, 楼敏, 陈智才, 陈红芳, 徐冬娟, 王志敏, 胡海芳, 吴承龙, 张晓玲, 马小董, 王亚仙, 胡海涛, 浙江省缺血性脑卒中静脉溶栓的临床行为干预研究协作组 . 医院内缺血性脑卒中患者静脉溶栓时间及预后分析[J]. 浙江大学学报(医学版), 2019, 48(3): 260-266.